What's new? Log in Free sign up

Industry / Surgical and Medical Instrument Manufacturing

Trending Companies

Companies in the news

Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Jefferies Maintains Buy on Stryker, Raises Price Target to $320

Boston Scientific

Analyst Expectations for Boston Scientific's Future

Becton, Dickinson And

Becton, Dickinson's Debt Overview

Expert Ratings for 3M

Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years

Alcon Inc. - Registered Shares

Mizuho Reiterates Buy on Alcon, Maintains $85 Price Target

$100 Invested In ResMed 5 Years Ago Would Be Worth This Much Today

Analyst Expectations for Insulet's Future

Price Over Earnings Overview: GE HealthCare Techs

Latest filings

All filings

Registration of securities for employees

BLFS Biolife Solutions

SSKN STRATA Skin Sciences

Notice of late annual filing

Disrupting Convention in Women’s Health Through Continuous Innovation March 2023 Corporate Presentation 1

Submission of Matters to a Vote of Security Holders

ICU SeaStar Medical Holding

Prospectus supplement

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares

ICU SeaStar Medical Holding

Prospectus supplement

Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders

Upcoming Earnings Releases

Earnings calendar

Bluejay Diagnostics

Treace Medical Concepts

Becton, Dickinson And

Latest IPO Filings (S1/F1/S11)

IPO calendar

GEHC GE HealthCare

RSLS ReShape Lifesciences

GTHP Guided Therapeutics

ICU SeaStar Medical Holding

VVOS Vivos Therapeutics

STSS Sharps Technology

NMRD Nemaura Medical

HSCS Heart Test Laboratories

Stock splits Upcoming and recent stock splits

Splits calendar

ReShape Lifesciences

Arch Therapeutics

Intelligent Bio Solutions

News

From Benzinga Pro

Neovasc Announces Q4 And FY22 Financial Results And Provides Corporate Update; FY22 Revenue $$3.8M Vs $2.55M YoY; FY22 EPS $(15.07) Vs $(9.88) YoY

Motus GI Hldgs Q4 Sales $109.00K Up From $99.00K YoY

Vivani Medical Reports Q4 And FY22 Financial Results And Provides Business Update; FY22 EPS $(0.36) Vs $(0.39) YoY; As Of December 31, 2022, Vivani Had Cash And Cash Equivalents Totaling $45.1M

Watching Lucid Diagnostics; Traders Circulate CMS.gov Link Titled 'MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia'

12 Health Care Stocks Moving In Friday's Intraday Session

Alliance Global Partners Maintains Buy on InspireMD, Lowers Price Target to $5.15

Here's How Much You Would Have Made Owning DexCom Stock In The Last 5 Years

Chardan Capital Maintains Buy Rating for Femasys: Here's What You Need To Know

Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Stocks That Hit 52-Week Lows On Friday

Press releases

From Benzinga Pro

Information on the Total Number of Voting Rights and Shares

Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

New to The Street Announces Corporate Guests Appearances for Airings on TV Episodes 454 and 455 Starting Saturday, April 1, 2023, at 3:30 PM ET

Tekla World Healthcare Fund Paid Distribution

Tekla Healthcare Investors Paid Distribution

Community annotations

Hi Greg, I did try to email you a while back on the email you sent me, but it didn't work. If you ping me, I'll try again

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Patents

Injectable Shear-thinning Hydrogel Containing Therapeutic Agent for Enhanced Tumor Therapy

Electrosurgical Apparatus with Flexible Shaft

Stent-valve Delivery System

Implantable Matrix for Treating Central Nervous System Disorders

Injectable Shear-thinning Hydrogel Containing Polypeptide Therapeutic Agent for Enhanced Tumor Therapy

Apparatus and Method for Maintaining Optical Ferrule Alignment During Thermal Expansion or Contraction

Dual Needle Valve for a Wearable Drug Delivery Device

Reactive Hydrogel Forming Formulations and Related Methods, Including Methods of Preparation

Patient Support Apparatus With An Accessory Support

System, Device, Product, Apparatus, and Method for Reading Syringe Information

Reddit threads

I’ve been scratching my head on why $PBTS hasn’t moved and today it looks like it’s finally going to start acting like a candidate from this list: $INUV $MARK $AMST $POAI $LTRN $OBLG https://finance.yahoo.com/news/7-ai-penny-stocks-could-171006875.html

Daily Discussion Thread - March 29th, 2023

Daily Plays March 29, 2023

Why I’m bullish on ATOS (Atossa Therapeutics) and you should be too.

smallstreetbets

What are the best performing positions in your portfolio?

Why I’m bullish on ATOS (Atossa Therapeutics) and you should be too.

Daily Discussion Thread - March 28th, 2023

Daily Discussion Thread - March 27th, 2023

Who Else Is Keeping Cash Ready Ahead of the Recession - Part II

🚨GUYS! Pls look at this. Any takes? 💎 or 💩 ?

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.